JAZZ vs RNA · P/E 1988, rev $2.28B vs rev $22.6M
Jazz Pharmaceuticals PLC (JAZZ) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. RNA currently screens at market cap $217.5M.
Not investment advice. Open the JAZZ and RNA stock pages for the full models.
Not investment advice.